Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could 'lung rest' on ECMO save more lives in severe ARDS?

NCT ID NCT06814340

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether giving the lungs a near-complete rest (apneic ventilation) early after starting ECMO helps people with the most severe form of acute respiratory distress syndrome (ARDS). About 280 participants will be randomly assigned to either near-apneic ventilation or standard ultra-protective lung ventilation. The goal is to see if this approach reduces lung injury, shortens time on ECMO, and improves survival at 60 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 280 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Severe acute respiratory distress syndrome refractory to conventional therapy placed on VV-ECMO support in the 48 hours (maximum tolerance : +2h) preceding inclusion. 2. Obtain informed consent from a close relative or surrogate. According to the specifications of emergency inclusion, randomization without the close relative/surrogate consent could be performed if the patient is unable to give his/her consent and when the close relative/surrogate/family member are absent. Close relative/surrogate/family member consent will be asked as soon as possible after randomization. The patient will be asked as soon as possible to give his/her consent for the continuation of the trial when his/her condition will allow. 3. French Social security registration (except AME) Exclusion Criteria: 1. Age \< 18 2. Pregnancy or breastfeeding 3. Initiation of VV-ECMO \> 48 h (maximum tolerance : +2h) 4. Cardiac arrest with cumulated no flow time \&amp;gt;10 minutes before ECMO (within 48 hours prior to inclusion) 5. Irreversible neurological pathology 6. End-stage chronic lung disease 7. Contraindications for high PEEP level: untreated pneumothorax, barotrauma 8. Irreversible ARDS with no hope for lung function recovery 9. Patient moribund on the day of randomization, SAPS II \&amp;gt;90 10. Liver cirrhosis (Child B or C) 11. Lung transplantation 12. Burns on more than 20 % of the body surface 13. Participation in another interventional study with a similar primary endpoint (mortality, lung transplantation, or duration of ECMO) or being in the exclusion period at the end of a previous study 14. Individuals under guardianship, or permanently legally incompetent adults

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute respiratory distress syndrome Extracorporeal membrane oxygenation complication

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Avicenne Hospital

    RECRUITING

    Bobigny, France

  • Brabois Hospital - CHRU Nancy

    RECRUITING

    Nancy, France

  • CHU Orléans

    RECRUITING

    Orléans, France

  • CHU Tours

    RECRUITING

    Tours, France

  • Croix-Rousse Hospital - HCL

    RECRUITING

    Lyon, France

  • Haut Levèque Hospital - CHU Bordeaux

    RECRUITING

    Bordeaux, France

  • Henri Mondor Hospital

    RECRUITING

    Créteil, France

  • Mercy Hospital - CHR Metz

    RECRUITING

    Metz, France

  • North Hospital - APHM

    RECRUITING

    Marseille, France

  • Pitié-Salpêtrière Hospital

    RECRUITING

    Paris, France

  • Pontchaillou Hospital - CHU Rennes

    RECRUITING

    Rennes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.